연구성과로 돌아가기

2024 연구자 정보 (698 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Park, Jong Heon
(Park, JH) ⓘ 		Natl Hlth Insurance Serv, Big Data Steering Dept, Goyang, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Park, Keun Yong
(Park, KY) ⓘ 		Konyang Univ, Coll Med, Dept Diagnost Radiol, Konyang Univ Hosp, Taejon 302718, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Park, So Young
(Park, SY) ⓘ 		Kyung Hee Univ, Coll Med, Dept Endocrinol & Metab, Seoul, South Korea
Eulji Univ, Dept Internal Med, Sch Med, Seoul, South Korea
Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea ⓘ
ⓘ 		0000-0002-4820-9415
PARK, SO YOUNG ⓘ 		[JCR상위 27.0] Bone Loss after Solid Organ Transplantation: A Review of Organ-Specific Considerations
[JCR상위 27.0] Effects of Endocrine-Disrupting Chemicals on Bone Health
[JCR상위 32.0] Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment
[JCR상위 21.8] Prospective direct comparison of biologic treatments for severe eosinophilic asthma Findings from the PRISM study ⓘ 		SCIE ⓘ 21.8 ENDOCRINOLOGY & METABOLISM
ALLERGY;IMMUNOLOGY ⓘ 		drbkh@catholic.ac.kr;
kjeun@knu.ac.kr;swkimmd@snu.ac.kr;
tbkim@amc.seoul.kr; ⓘ
Ryu, Ohk-Hyun
(Ryu, OH) ⓘ 		Hallym Univ, Div Endocrinol & Metab, Coll Med, Chuncheon Si, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Song, Keeho
(Song, KH) ⓘ 		Konkuk Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Won, Kyu Chang
(Won, KC) ⓘ 		교신저자 Yeungnam Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, 170 Hyeonchung Ro, Daegu 42415, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Yu, Hea Min
(Yu, HM) ⓘ 		Eulji Univ, Daejeon Eulji Med Ctr, Dept Internal Med, Daejeon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Yu, Jae Myung
(Yu, JM) ⓘ 		Hallym Univ, Dept Internal Med, Kangnam Sacred Heart Hosp, Coll Med, Anyang, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) ⓘ SCIE ⓘ 27.0 ENDOCRINOLOGY & METABOLISM ⓘ kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; ⓘ
Ahn, Hee Kyung
(Ahn, HK) ⓘ 		Gachon Univ, Div Med Oncol, Dept Internal Med, Gil Med Ctr, Incheon, South Korea
Gachon Univ, Dept Internal Med, Gil Med Ctr, Incheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) ⓘ SCIE ⓘ 27.1 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu; ⓘ
Ahn, Jin Seok
(Ahn, JS) ⓘ 		Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) ⓘ SCIE ⓘ 27.1 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu; ⓘ
An, Hyonggin
(An, H) ⓘ 		Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) ⓘ SCIE ⓘ 27.1 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu; ⓘ
Byun, Jae-Ho
(Byun, JH) ⓘ 		Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Internal Med, Incheon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) ⓘ SCIE ⓘ 27.1 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu; ⓘ
Chae, Yeesoo
(Chae, Y) ⓘ 		Kyungpook Natl Univ, Dept Internal Med, Chilgok Hosp, Daegu, South Korea
Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
[JCR상위 8.7] First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results ⓘ 		SCIE ⓘ 8.7 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu;
p.schmid@qmul.ac.uk; ⓘ
Deena, S. R.
(Deena, SR) ⓘ 		Saveetha Inst Med & Tech Sci SIMATS, Saveetha Sch Engn, Dept Biotechnol, Chennai 602105, Tamil Nadu, India ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] Systematic Assessment of Mechanisms, Developments, Innovative Solutions, and Future Perspectives of Microplastics and Ecotoxicity - A Review ⓘ SCIE ⓘ 27.1 GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY;MATERIALS SCIENCE, MULTIDISCIPLINARY ⓘ kanishkarmegam@gmail.com;gova.muthu@gmail.com; ⓘ
Hyun Kim, Jee
(Kim, JH) ⓘ 		Seoul Natl Univ, Seoul Natl Univ Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 27.1] A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) ⓘ SCIE ⓘ 27.1 ONCOLOGY ⓘ oncolee@ewha.ac.kr;yhparkhmo@skku.edu; ⓘ
페이지 이동: